Avita Medical Inc

Financials

Mittelzufluss aus laufender Geschäftstätigkeit -8.08 M-10.31 M-10.23 M-5.22 M-5.44 M -31.2 M Mittelzufluss aus Investitionstätigkeit 2.47 M10.77 M7.02 M-5.34 M11 K 12.45 M Zahlungsströme aus der Finanzierungstätigkeit 1.02 M363 K559 K13.77 M248 K 14.94 M Freier Cashflow -9.71 M-10.54 M-10.75 M-6.17 M-4.83 M -32.3 M

Avita Medical is a clinical and commercial company developing and marketing a range regenerative medicine products. The first regenerative medicine product brought to the market by Avita Medical was ReCell spray-on skin for the treatment of burns. The two latest products are ReNovaCell, for Aesthetics and Plastic applications including skin trauma, and ReGenerCell for the treatment of chronic wounds. The Avita Medical regenerative product range is currently marketed in Europe, the Middle East, Africa and Australia.

RCEL

Financials

Avita Medical Inc

Nachrichten

Avita Medical (RCEL) Soars 14.1%: Is Further Upside Left in the Stock?

AVITA Medical: Why The BARDA Rally Changes Nothing (NASDAQ:RCEL)

AVITA Medical sichert sich 25,5-Millionen-Dollar-Vertrag mit BARDA zur Katastrophenvorsorge

Avita Medical at TD Cowen Conference: Growth and Strategic Focus

Wall Street Analysts Believe Avita Medical (RCEL) Could Rally 29.87%: Here's is How to Trade

Avita Medical (RCEL) Upgraded to Buy: Here's What You Should Know

AVITA Medical, Inc. (RCEL) Discusses Financial Performance, Sales Strategy, and Reimbursement Progress Transcript

AVITA Medical, Inc. (RCEL) Q4 2025 Earnings Call Transcript

Avita Medical Q4 2025 slides: 11% annual growth with 12-19% expansion targeted for 2026

Avita Medical: Stabiler Umsatz in Q4 2025, Aktie gibt nachbörslich nach

Avita Medical Stock: Skin Regeneration Platform Is Set Up For A Turnaround (NASDAQ:RCEL)

AVITA Medical, Inc. (RCEL) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript